KalVista Pharmaceuticals ... (KALV)
| Bid | 8.33 |
| Market Cap | 536.19M |
| Revenue (ttm) | 1.28M |
| Net Income (ttm) | -165.51M |
| EPS (ttm) | -3.68 |
| PE Ratio (ttm) | -2.95 |
| Forward PE | -3.19 |
| Analyst | Buy |
| Ask | 11.75 |
| Volume | 921,987 |
| Avg. Volume (20D) | 378,575 |
| Open | 11.18 |
| Previous Close | 11.39 |
| Day's Range | 10.71 - 11.69 |
| 52-Week Range | 7.30 - 15.50 |
| Beta | 0.85 |
About KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ...
Analyst Forecast
According to 8 analyst ratings, the average rating for KALV stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 102.76% from the latest price.
2 months ago · seekingalpha.com
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the F...
